How Will the Market React to Phio Pharmaceuticals Corp (PHIO) Stock Getting a Bullish Rating

Tuesday, August 11, 2020 1:29 PM | InvestorsObserver Analysts

The market has been high on Phio Pharmaceuticals Corp (PHIO) stock recently. PHIO gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bullish
Phio Pharmaceuticals Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PHIO!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Recent trends are a good indator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With PHIO Stock Today?

Phio Pharmaceuticals Corp (PHIO) stock is trading at $3.05 as of 1:26 PM on Tuesday, Aug 11, a rise of $0.11, or 3.74% from the previous closing price of $2.94. The stock has traded between $2.91 and $3.17 so far today. Volume today is above average. So far 810,105 shares have traded compared to average volume of 556,582 shares.

To see InvestorsObserver's Sentiment Score for Phio Pharmaceuticals Corp click here.

More About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Close Update: Stocks Rally Friday Led by Technology to End Week Mixed

Wild Week Ends Up K Shaped

Sector Update: Biotech Stocks Lifting Health Care Sector to Big Advance

Stocks Shrug Off Early Weakness, Poised to Close Sharply Higher

Sector Update: Health Care

Is it Time to Dump Columbia Care Inc (CCHWF) Stock After it Is Down 4.62% in a Week?

Related Companies